Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

157
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
157
Clinical Trials01:16

Clinical Trials

6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Pharmacovigilance01:19

Pharmacovigilance

951
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
951
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

173
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
173
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

222
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
222

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of ethnicity in clinical trials: Delphi survey and consensus statement.

BMJ (Clinical research ed.)·2026
Same author

Protocol for a SPIRIT extension for reporting pragmatic and explanatory trial protocols designed using the PRECIS tool (SPIRIT-PRECIS).

Journal of clinical epidemiology·2026
Same author

SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

Lancet (London, England)·2026
Same author

SPIRIT-Children and Adolescents (SPIRIT-C) 2026 extension statement: enhancing the reporting and usefulness of paediatric randomised trial protocols.

The Lancet. Child & adolescent health·2026
Same author

CONSORT-Children and Adolescents (CONSORT-C) 2026 extension statement: enhancing the reporting and impact of paediatric randomised trials.

The Lancet. Child & adolescent health·2026
Same author

Reporting of Cohort and Routinely Collected Data in Randomised Controlled Trial Protocols (SPIRIT-ROUTINE): extension checklist with explanation and elaboration.

BMJ (Clinical research ed.)·2026

Related Experiment Video

Updated: Aug 17, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K

Surrogate endpoints in trials: a call for better reporting.

Oriana Ciani1, Anthony M Manyara2, An-Wen Chan3

  • 1SDA Bocconi School of Management, Milan, Italy.

Trials
|December 12, 2022
PubMed
Summary

Developing reporting guidelines for randomized controlled trials (RCTs) using surrogate endpoints is crucial for efficiency. This initiative aims to extend SPIRIT and CONSORT standards to improve trial reporting transparency and reliability.

Keywords:
Randomised trialsSurrogate endpoints

More Related Videos

Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies
09:53

Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies

Published on: November 30, 2016

12.3K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K

Related Experiment Videos

Last Updated: Aug 17, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies
09:53

Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies

Published on: November 30, 2016

12.3K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Evidence-Based Medicine

Background:

  • Randomized controlled trials (RCTs) increasingly use surrogate endpoints to expedite research and reduce costs.
  • The validity and reporting of surrogate endpoints in clinical trials lack standardized guidelines, leading to potential controversies.
  • Existing reporting guidelines like SPIRIT and CONSORT do not specifically address the nuances of surrogate endpoint utilization.

Discussion:

  • The development of extensions for SPIRIT and CONSORT is proposed to enhance the reporting quality of RCTs employing surrogate endpoints.
  • Standardized reporting will improve the interpretation and comparability of trial results based on surrogate outcomes.
  • Addressing the controversy surrounding surrogate endpoints requires clear methodological and reporting frameworks.

Key Insights:

  • Surrogate endpoints offer efficiency gains in clinical trials but necessitate rigorous reporting standards.
  • There is a critical need for guidelines to ensure transparency and reduce ambiguity in trials using surrogate outcomes.
  • Collaboration among methodologists, editors, industry, regulators, and patient groups is essential for guideline development.

Outlook:

  • The proposed SPIRIT and CONSORT extensions aim to establish best practices for reporting RCTs with surrogate endpoints.
  • Improved reporting will foster greater confidence in trial findings and support informed clinical decision-making.
  • Future research should focus on validating surrogate endpoints and refining reporting recommendations.